Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Neuropeptides ; 61: 31-37, 2017 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-27522536

RESUMO

The objective of this study is to examine the effects of the endogenous ligands leptin, ghrelin, and neuropeptide Y (NPY) on seizure generation, the oxidant/antioxidant balance, and cytokine levels, which are a result of immune response in a convulsive seizure model. With this goal, Wistar rats were divided into 5 groups-Group 1: Saline, Group 2: Saline+PTZ (65mg/kg), Group 3: leptin (4mg/kg)+PTZ, Group 4: ghrelin (80µg/kg)+PTZ, and Group 5: NPY (60µg/kg)+PTZ. All injections were delivered intraperitoneally, and simultaneous electroencephalography (EEG) records were obtained. Seizure activity was scored by observing seizure behavior, and the onset time, latency, and seizure duration were determined according to the EEG records. At the end of the experiments, blood samples were obtained in all groups to assess the serum TNF-α, IL-1ß, IL-6, FGF-2, galanin, nitric oxide (NOÖ¹), malondialdehyde (MDA), and glutathione (GSH) levels. The electrophysiological and biochemical findings (p<0.05) of this study show that all three peptides have anticonvulsant effects in the pentylenetetrazol (PTZ)-induced generalized tonic-clonic convulsive seizure model. The reduction of the levels of the pro-inflammatory cytokines TNF-α, IL-1ß, and IL-6 caused by leptin, ghrelin, and NPY shows that these peptides may have anti-inflammatory effects in epileptic seizures. Also, leptin significantly increases the serum levels of the endogenous anticonvulsive agent galanin. The fact that each one of these endogenous peptides reduces the levels of MDA and increases the serum levels of GSH leads to the belief that they may have protective effects against oxidative damage that is thought to play a role in the pathogenesis of epilepsy. Our study contributes to the clarification of the role of these peptides in the brain in seizure-induced oxidative stress and immune system physiology and also presents new approaches to the etiology and treatment of tendency to epileptic seizures.


Assuntos
Citocinas/sangue , Fator 2 de Crescimento de Fibroblastos/sangue , Galanina/sangue , Grelina/farmacologia , Leptina/farmacologia , Neuropeptídeo Y/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Convulsões/metabolismo , Animais , Modelos Animais de Doenças , Interleucina-1beta/sangue , Interleucina-6/sangue , Malondialdeído/sangue , Pentilenotetrazol , Ratos , Ratos Wistar , Convulsões/induzido quimicamente , Fator de Necrose Tumoral alfa/sangue
2.
J Crit Care ; 34: 89-94, 2016 08.
Artigo em Inglês | MEDLINE | ID: mdl-27288617

RESUMO

PURPOSE: The recognition of acute kidney injury (AKI) as early as possible is important in the intensive care unit. This study proposes that serum and urine levels of neutrophil gelatinase-associated lipocalin (NGAL) may be used for this purpose. METHODS: One hundred and seven critically ill adult patients with no previous renal failure were included. NGAL levels were measured during the first 48 hours after admission; NGAL levels were followed for 7 days and classified based on Risk, Injury, Failure, Loss, and End-Stage Renal Failure criteria. RESULTS: The AKI incidence was 35.5%, and serum NGAL (sNGAL) and urinary NGAL (uNGAL) levels were higher in the AKI group. The area under the receiver operating characteristic curve was 0.76 (P<.001) for sNGAL and 0.75 (P<.001) for uNGAL. Seventy-one percent of AKI cases were observed within 48 hours, with 11 additional cases in the ensuing 7 days. The mean serum creatinine levels in the 11 patients were not different from non-AKI levels (P=.197), but the NGAL values were different, and the area under the receiver operating characteristic curve for sNGAL uNGAL was 1.00 (P=.014) and 0.93 (P=.02), respectively. CONCLUSIONS: Most AKI cases were diagnosed within the first 48 hours after admission, and NGAL was useful for predicting upcoming AKI.


Assuntos
Injúria Renal Aguda/sangue , Lipocalina-2/sangue , Injúria Renal Aguda/diagnóstico , Injúria Renal Aguda/urina , Adulto , Idoso , Área Sob a Curva , Biomarcadores/sangue , Biomarcadores/urina , Cuidados Críticos , Estado Terminal , Diagnóstico Precoce , Feminino , Humanos , Unidades de Terapia Intensiva , Lipocalina-2/urina , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Curva ROC , Sensibilidade e Especificidade
3.
Bosn J Basic Med Sci ; 13(4): 242-7, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24289760

RESUMO

Epilepsy is one of the most common neurological disorders, characterized by recurrent seizures, which may increase the content of reactive oxygen and nitrogen species. The objective of this study was to investigate the effects of Neuropeptide Y on oxidative and nitrosative balance and brain-derived neurotrophic factor levels induced by pentylenetetrazole (a standard convulsant drug) in the hippocampus of Wistar rats. Three groups of seven rats were treated intraperitoneally as follows: group 1 (saline + saline) 1 ml saline, group 2 (salin + Pentylenetetrazole) 1 ml saline 30 min before Pentylenetetrazole; and group 3 (Neuropeptide Y + Pentylenetetrazole) 60 µg/kg Neuropeptide Y 30 min before 60 mg/kg Pentylenetetrazole. After 24 h, the animals were euthanized by decapitation. Hippocampus were isolated to evaluate the malondialdehyde, glutathione, nitric oxide, and brain-derived neurotrophic factor levels in three rat groups. The results of this study demonstrated that while intraperitoneally administered neuropeptide Y did not result in a statistically significant difference in BDNF levels, its administration caused a statistically significant decrease in malondialdehyde and nitric oxide levels and an increase in glutathione levels in rats with pentylenetetrazole-induced epileptic seizure. Neuropeptide Y were able to reduce nitroxidative damage induced by pentylenetetrazole in the hippocampus of Wistar rats.


Assuntos
Epilepsia/tratamento farmacológico , Epilepsia/metabolismo , Hipocampo/efeitos dos fármacos , Hipocampo/metabolismo , Neuropeptídeo Y/administração & dosagem , Animais , Fator Neurotrófico Derivado do Encéfalo/metabolismo , Convulsivantes/toxicidade , Modelos Animais de Doenças , Epilepsia/induzido quimicamente , Glutationa/metabolismo , Masculino , Malondialdeído/metabolismo , Neuropeptídeo Y/metabolismo , Óxido Nítrico/metabolismo , Pentilenotetrazol/toxicidade , Ratos , Ratos Wistar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...